BB&T Corp boosted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 4.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 211,405 shares of the company’s stock after buying an additional 9,174 shares during the period. BB&T Corp owned approximately 0.31% of Myriad Genetics worth $5,463,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of MYGN. Norges Bank bought a new position in Myriad Genetics during the fourth quarter worth about $14,319,000. Arizona State Retirement System bought a new position in Myriad Genetics during the first quarter worth about $682,000. Dimensional Fund Advisors LP boosted its position in Myriad Genetics by 14.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,654,854 shares of the company’s stock worth $27,587,000 after buying an additional 204,049 shares in the last quarter. Comerica Bank boosted its position in Myriad Genetics by 4.8% in the fourth quarter. Comerica Bank now owns 51,750 shares of the company’s stock worth $845,000 after buying an additional 2,348 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Myriad Genetics by 131.2% in the first quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock worth $17,632,000 after buying an additional 521,146 shares in the last quarter.
Myriad Genetics, Inc. (NASDAQ MYGN) traded up 3.37% during mid-day trading on Friday, hitting $28.80. 1,315,637 shares of the stock were exchanged. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of 90.28 and a beta of 0.31. Myriad Genetics, Inc. has a 52-week low of $15.15 and a 52-week high of $29.01. The company has a 50 day moving average price of $25.48 and a 200 day moving average price of $21.36.
Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.26 by $0.04. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The firm had revenue of $200.50 million during the quarter, compared to the consensus estimate of $193.71 million. During the same quarter in the prior year, the firm earned $0.36 EPS. Myriad Genetics’s revenue for the quarter was up 7.5% on a year-over-year basis. On average, analysts anticipate that Myriad Genetics, Inc. will post $1.02 EPS for the current year.
A number of research analysts have issued reports on MYGN shares. Jefferies Group LLC reaffirmed a “hold” rating and issued a $21.00 price target (up previously from $18.00) on shares of Myriad Genetics in a report on Wednesday, May 3rd. Deutsche Bank AG raised their price target on shares of Myriad Genetics from $15.00 to $20.00 and gave the stock a “sell” rating in a report on Monday, May 8th. BidaskClub raised shares of Myriad Genetics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. J P Morgan Chase & Co reaffirmed an “underweight” rating and issued a $16.00 price target on shares of Myriad Genetics in a report on Friday, June 30th. Finally, Cowen and Company reaffirmed a “hold” rating and issued a $25.00 price target on shares of Myriad Genetics in a report on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the company’s stock. Myriad Genetics has a consensus rating of “Hold” and an average target price of $21.22.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.